35286997|t|Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models.
35286997|a|Accumulation of amyloid-beta (Abeta) oligomers and phosphorylated Tau aggregates are crucial pathological events or factors that cause progressive neuronal loss, and cognitive impairments in Alzheimer's disease (AD). Current medications for AD have failed to halt, much less reverse this neurodegenerative disorder; therefore, there is an urgent need for the development of effective and safe drugs for AD therapy. In the present study, the in vivo therapeutic efficacy of an Abeta-oligomer-targeted fluorescent probe, F-SLOH, was extensively investigated in 5XFAD and 3XTg-AD mouse models. We have shown that F-SLOH exhibits an efficient inhibitory activity against Abeta aggregation in vivo, and acts as an effective theranostic agent for the treatment of multiple neuropathological changes in AD mouse models. F-SLOH has been found to significantly reduce not only the levels of Abeta oligomers, Tau aggregates and plaques but also the levels of amyloid precursor protein (APP) and its metabolites via autophagy lysosomal degradation pathway (ALP) in the brains of 5XFAD and 3XTg-AD mice. It also reduces astrocyte activation and microgliosis ultimately alleviating neuro-inflammation. Furthermore, F-SLOH mitigates hyperphosphorylated Tau aggregates, synaptic deficits and ameliorates synaptic memory function, and cognitive impairment in AD mouse models. The mechanistic studies have shown that F-SLOH promotes the clearance of C-terminal fragment 15 (CTF15) of APP and Paired helical filaments of Tau (PHF1) in stable cell models via the activation of transcription factor EB (TFEB). Moreover, F-SLOH promotes ALP and lysosomal biogenesis for the clearance of soluble, insoluble Abeta, and phospho Tau. Our results unambiguously reveal effective etiological capabilities of theranostic F-SLOH to target and intervene multiple neuropathological changes in AD mouse models. Therefore, F-SLOH demonstrates tremendous therapeutic potential for treating AD in its early stage.
35286997	12	18	F-SLOH	Chemical	-
35286997	29	48	Alzheimer's disease	Disease	MESH:D000544
35286997	69	73	TFEB	Gene	21425
35286997	113	132	Alzheimer's disease	Disease	MESH:D000544
35286997	171	176	Abeta	Gene	11820
35286997	288	301	neuronal loss	Disease	MESH:D009410
35286997	307	328	cognitive impairments	Disease	MESH:D003072
35286997	332	351	Alzheimer's disease	Disease	MESH:D000544
35286997	353	355	AD	Disease	MESH:D000544
35286997	382	384	AD	Disease	MESH:D000544
35286997	429	455	neurodegenerative disorder	Disease	MESH:D019636
35286997	544	546	AD	Disease	MESH:D000544
35286997	617	622	Abeta	Gene	11820
35286997	660	666	F-SLOH	Chemical	-
35286997	700	705	5XFAD	CellLine	CVCL:5U93
35286997	710	714	3XTg	CellLine	CVCL:C6V6
35286997	715	717	AD	Disease	MESH:D000544
35286997	718	723	mouse	Species	10090
35286997	751	757	F-SLOH	Chemical	-
35286997	808	813	Abeta	Gene	11820
35286997	908	925	neuropathological	Disease	MESH:D009422
35286997	937	939	AD	Disease	MESH:D000544
35286997	940	945	mouse	Species	10090
35286997	954	960	F-SLOH	Chemical	-
35286997	1023	1028	Abeta	Gene	11820
35286997	1090	1115	amyloid precursor protein	Gene	11820
35286997	1209	1214	5XFAD	CellLine	CVCL:5U93
35286997	1219	1223	3XTg	CellLine	CVCL:C6V6
35286997	1224	1226	AD	Disease	MESH:D000544
35286997	1227	1231	mice	Species	10090
35286997	1274	1286	microgliosis	Disease	
35286997	1310	1328	neuro-inflammation	Disease	MESH:D007249
35286997	1343	1349	F-SLOH	Chemical	-
35286997	1396	1404	synaptic	Disease	MESH:D012183
35286997	1430	1438	synaptic	Disease	MESH:D012183
35286997	1460	1480	cognitive impairment	Disease	MESH:D003072
35286997	1484	1486	AD	Disease	MESH:D000544
35286997	1487	1492	mouse	Species	10090
35286997	1541	1547	F-SLOH	Chemical	-
35286997	1649	1653	PHF1	Gene	21652
35286997	1699	1722	transcription factor EB	Gene	21425
35286997	1724	1728	TFEB	Gene	21425
35286997	1741	1747	F-SLOH	Chemical	-
35286997	1826	1831	Abeta	Gene	11820
35286997	1933	1939	F-SLOH	Chemical	-
35286997	1973	1990	neuropathological	Disease	MESH:D009422
35286997	2002	2004	AD	Disease	MESH:D000544
35286997	2005	2010	mouse	Species	10090
35286997	2030	2036	F-SLOH	Chemical	-
35286997	2096	2098	AD	Disease	MESH:D000544
35286997	Association	MESH:D000544	11820
35286997	Association	MESH:D003072	11820
35286997	Association	MESH:D000544	21425
35286997	Positive_Correlation	MESH:D009410	11820

